STOCK TITAN

Corcept Therapeutics director sells 1,500 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics Inc. director Daniel N. Swisher Jr. exercised options to acquire 1,100 common shares at $14.0800 per share and 400 shares at $10.5000 per share on November 10, 2026, and reported a sale of 1,500 common shares at $74.0700 per share that day. The sale was made pursuant to a Rule 10b5-1 plan adopted August 3, 2026; both options were fully exercisable. A footnote to the 400-share option says he previously transferred 12,500 shares underlying the option to his ex-spouse and no longer reports securities owned by her as beneficially owned.

Insider Swisher Daniel N JR
Role Director
Sold 1,500 shs ($111K)
Approx. gross sale proceeds $111K
Approx. exercise cost $20K
Approx. pre-tax spread $91K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F2 1,100 $0.00 $0.00
Exercise Stock Option (right to buy) F2, F3 400 $0.00 $0.00
Exercise Common Stock 1,100 $14.08 $15K
Exercise Common Stock 400 $10.50 $4K
Sale Common Stock F1 1,500 $74.07 $111K
Holdings After Transaction: Stock Option (right to buy) — 12,100 options (Direct); Common Stock — 0 shares (Direct)
Footnotes (3)
  1. F1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 3, 2026 in effect at the time of this transaction.
  2. F2. Fully exercisable.
  3. F3. The Reporting Person previously transferred 12,500 shares underlying the stock option to his ex-spouse. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Shares sold 1,500 shares Common shares sold on November 10, 2026
Sale price $74.0700 per share Sale on November 10, 2026
Option exercise 1,100 shares at $14.0800 per share Common shares acquired upon option exercise on November 10, 2026
Option exercise 400 shares at $10.5000 per share Common shares acquired upon option exercise on November 10, 2026
10b5-1 plan regulatory
"transaction was made pursuant to a 10b5-1 plan adopted"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
Fully exercisable financial
"Fully exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares did director Daniel N. Swisher Jr. sell, and at what price?

Daniel N. Swisher Jr., a director of Corcept Therapeutics Inc., sold 1,500 common shares at $74.0700 per share on November 10, 2026. The sale was made pursuant to a Rule 10b5-1 plan adopted August 3, 2026.

What CORT stock options did Daniel N. Swisher Jr. exercise?

On November 10, 2026, he exercised options to acquire 1,100 common shares at $14.0800 per share and 400 common shares at $10.5000 per share. Both options were fully exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Swisher Daniel N JR

(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/10/2026M1,100A$14.081,100D
Common Stock11/10/2026M400A$10.51,500D
Common Stock11/10/2026S(1)1,500D$74.070D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$14.0811/10/2026M1,100 (2)08/20/2028Common Stock1,100$0.000D
Stock Option (right to buy)$10.511/10/2026M400 (2)06/18/2029Common Stock400$0.0012,100(3)D
Explanation of Responses:
1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 3, 2026 in effect at the time of this transaction.
2. Fully exercisable.
3. The Reporting Person previously transferred 12,500 shares underlying the stock option to his ex-spouse. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Daniel N. Swisher, Jr.11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading